Lupin Ltd (LUPIN)

Lupin Receives FDA Approval for Generic Eye Medication - 26 Apr, 2024

The USFDA has approved Lupin's generic equivalent of Bausch & Lomb's Lotemax ophthalmic suspension. The product had estimated annual sales of $59 million in the US.

Lupin Receives Establishment Inspection Report from USFDA for Aurangabad Facility - 24 Apr, 2024

Lupin Ltd has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for its Aurangabad manufacturing facility. The facility was classified as Voluntary Action Indicated (VAI). Lupin's board of directors will hold a meeting on May 6, 2024. The stock rose on BSE following the news.

Lupin's Aurangabad facility receives VAI classification from US FDA - 23 Apr, 2024

The United States Food and Drug Administration (U.S. FDA) has classified Lupin's Aurangabad manufacturing facility as Voluntary Action Indicated (VAI) after an inspection conducted in March 2024.

Lupin Launches New Drug in US Market - 22 Apr, 2024

Pharmaceutical major Lupin launched Mirabegron Extended-Release Tablets, 25 mg in the US after receiving approval from the US FDA. The drug had estimated annual sales of $1,019 million in the US. Adlytick recommended Lupin as a defensive pick in a volatile market.

Lupin Gets USFDA Nod for Generic Overactive Bladder Tablet - 21 Apr, 2024

The USFDA has granted Lupin approval to launch a generic tablet to treat overactive bladder. Despite this positive news, Lupin shares fell nearly 3% on Friday, closing at ₹1,547 apiece on the NSE. However, the stock price has surged by almost 18% so far this year and gained 120% in the last one year.

Lupin Ltd's High P/S Ratio May Not Be Sustainable - 20 Apr, 2024

Lupin Ltd has a high P/S ratio due to strong revenue growth, but analysts predict it will only match industry growth. The current share price may not be sustainable unless the company outperforms in the short term.

Sharekhan Recommends Buying Lupin with Target Price of Rs. 1868 - 16 Apr, 2024

Lupin's US sales are expected to reach $1 billion by FY2026, and EBITDA margin is expected to rise to a five-year high at 21%. Sharekhan recommends buying Lupin with a target price of Rs. 1868 due to healthy uptick in respiratory portfolio led by gSpiriva witnessing a 30-35% conversion rate.

Lupin Forecasts $200-210 Million Quarterly Sales for US Operations - 15 Apr, 2024

Lupin expects to generate $200-210 million in quarterly sales from its US operations this year, with the respiratory portfolio driving future revenue growth. The company also plans to diversify into other therapeutic areas such as injectables.

Lupin Reports Strong Q3 Results and Successful FDA Inspection - 12 Apr, 2024

Lupin Ltd shares rose over 2% after the company announced successful closure of inspections by the USFDA at its Vadodara facility. The pharmaceutical company reported a consolidated net profit of Rs 613.12 crore in Q3 FY24, growing 299.6% YoY, while revenue from operations increased 20.2% YoY to Rs 5,197.4 crore. Lupin's API manufacturing facility located at Dabhasa, Gujarat has completed the USFDA inspection with no observations.

Lupin Launches First Generic Version of Oracea in US Market; Receives Approval from USFDA - 10 Apr, 2024

Lupin has launched its first generic version of Oracea in the US market after receiving approval from the USFDA. Brokerage Nomura has maintained a buy rating on Lupin with an increased target price of Rs 1,949 per share. The company also recalled Rifampin Capsules due to subpotency.

Lupin Launches Generic Version of Oracea and Secures Approval for Tardive Dyskinesia Treatment Drug - 09 Apr, 2024

Lupin has launched a generic version of Oracea skin treatment capsules in the US and secured FDA approval for selling Valbenazine Capsules, used to treat involuntary movements resulting from tardive dyskinesia. However, Lupin is recalling 26,352 bottles of Rifampin capsules in the US market due to a sub-potent drug identified from its Aurangabad plant.

Lupin Receives FDA Approval for Generic Equivalent - 08 Apr, 2024

Lupin Limited has received FDA approval to market Valbenazine Capsules, a generic equivalent of Neurocrine Biosciences' Ingrezza Capsules, used to treat involuntary movements caused by tardive dyskinesia.

Lupin Appoints Dr. Ranjana Pathak as Chief Quality Officer - 04 Apr, 2024

Dr. Ranjana Pathak has been appointed as the new Chief Quality Officer of Lupin Limited, succeeding Johnny Mikell who is retiring. With over three decades of industry experience, Pathak will oversee all aspects of quality and regulatory compliance for Lupin's global operations.

Lupin's Q3 Net Profit Soars to Rs 916 Crore - 03 Apr, 2024

Lupin Ltd reported a net profit of Rs 916 crore in the December quarter, up from Rs 40.4 crore a year ago. Its operating profit margins expanded to 29.58 percent and revenue jumped to Rs 4,138 crore. SBI Securities is bullish on the stock given its strong quarterly results, leadership in certain geographies, and strong product portfolio and pipeline.

Lupin Receives Multiple FDA Approvals - 01 Apr, 2024

Lupin has received multiple approvals from the USFDA for its drugs, including Eslicarbazepine Acetate tablets and Migalastat Capsules, potentially granting the company 180-day exclusivity with estimated sales of $354 million.

Lupin Receives US FDA Approval for Generic Drug; Expects Strong Revival in US Market - 29 Mar, 2024

Lupin has received US FDA approval for its ANDA for Eslicarbazepine Acetate Tablets and may be eligible for 180 days of shared generic exclusivity. Lupin also expects a strong revival in the US market with the launch of gSpiriva, which could generate $150-200 million in sales in the first year alone.

Lupin Stock Surges; Receives FDA Approval for Generic Drug - 28 Mar, 2024

Lupin Ltd's stock has surged 146% over the past year and gained 22% YTD. The company received USFDA approval to market Eslicarbazepine Acetate tablets, with estimated annual sales of $354 million in the US.